Provectus生物制药公司(Provectus Biopharmaceuticals, Inc.)报告称,其膀胱灌注型药物PV-10在每剂3毫克的剂量下,因引发急性黏膜毒性而未能被患者耐受。
Provectus生物制药公司(Provectus Biopharmaceuticals, Inc.)报告称,其膀胱灌注型药物PV-10在每剂3毫克的剂量下,因引发急性黏膜毒性而未能被患者耐受。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.